CJ
RARE icon

Caitlin John’s Ultragenyx Pharmaceutical RARE Stock Holding History

Caitlin John’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$105 – 1045
2026
Q1 		$105 Hold
5
– – ﹤0.01% 914
2025
Q4 		$115 Hold
5
– – ﹤0.01% 903
2025
Q3 		$150 Buy
+5
New +$150 ﹤0.01% 851
2025
Q1 		– Sell
-5
Closed -$210 – 633
2024
Q4 		$210 Hold
5
– – ﹤0.01% 817
2024
Q3 		$244 Hold
5
– – ﹤0.01% 803
2024
Q2 		$206 Buy
+5
New +$213 ﹤0.01% 805

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Caitlin John's RARE Position: Q2 2026 in Review

Caitlin John sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 5 shares — an estimated $105 sold.

Caitlin John first reported a position in RARE in Q2 2024 and held it in 6 quarters. The position peaked at $244 in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Caitlin John reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Caitlin John sold 5 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $105.
  • Caitlin John first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and held it in 6 quarters.
  • Caitlin John's Ultragenyx Pharmaceutical position peaked at $244 in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Caitlin John's 13F filing for Q2 2026, filed 17 Aug 2026.